GO
| HSI1 | 26,629.96 | +44.90 | 234.86B |
| HSCEI1 | 9,114.30 | -8.65 | 89.86B |
| Back Zoom + Zoom - Block Traded | |
|
2026-01-22 10:51:55 China's National Healthcare Security Administration released on January 20 the Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial) and held a press briefing in Beijing, according to JPMorgan's report. JPMorgan believes these guidelines will have a structurally positive impact on the Chinese surgical robot market, since they will establish a consistent pricing path while promoting the industry's transition towards a value-oriented and tiered reimbursement model. The report highlighted MEDBOT-B (02252.HK)'s rally of about 15% on the day of the announcement amid the market's highly positive response, reflecting improved visibility of the company's reimbursement mechanism and a clearer commercialization path. JPMorgan has given MEDBOT-B an Overweight rating and a target price of HKD42. ~ AAStocks Financial News Web Site: www.aastocks.com | |